Anna Solum, MD
Endocrinology, Diabetes & Metabolism · Burlington, NCNPI 1073585618
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,992 of the $29,139 with a category attached, or 68.6%. AstraZeneca accounts for 75.1% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2020 at $10,471 and has fallen 90.2% since, to $1,031 in 2025.
Across 131 payments — averaging $222.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$22K
- Mannkind Corporation$4K
- Sanofi US Services Inc.$325
- Novo Nordisk$304
- Abbott$268
- Dexcom, Inc.$251
- plus $2K from 20 others
What the payments were for
- Consulting fees$3,65013%
- Speaking & faculty fees$19,99269%
- Travel & lodging$2,5649%
- Food & beverage$2,90010%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $21,886 |
| Mannkind Corporation | 17 | $4,091 |
| Sanofi US Services Inc. | 1 | $325 |
| Novo Nordisk | 11 | $304 |
| Abbott | 14 | $268 |
| Dexcom, Inc. | 3 | $251 |
| Insulet Corporation | 10 | $236 |
| Lilly USA, LLC | 12 | $196 |
| BETA Bionics, Inc. | 2 | $186 |
| Sanofi | 2 | $180 |
| Amgen | 1 | $175 |
| Madrigal Pharmaceuticals | 2 | $160 |
| Ascendis Pharma Endocrinology Inc | 3 | $153 |
| Amneal Pharmaceuticals LLC | 1 | $147 |
| Radius Health, Inc. | 5 | $115 |
| Kyowa Kirin, Inc. | 1 | $107 |
| Sanofi-aventis U.S. LLC | 2 | $103 |
| Medtronic(2 entities) | 3 | $55 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Sequel Med Tech, LLC | 1 | $34 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Novartis | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
| Cequr Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$21,471
- AFREZZA$3,817
- iLet Bionic Pancreas$516
- SOLIQUA 100/33$325
- DEXCOM G6 TRANSMITTER$242
- Prolia$175
- iLet Insulin Infusion Kit Inset$172
- iLet Insulin Infusion Kit Contact Detach$172
- REZDIFFRA$133
- Yorvipath$122
- TOUJEO$110
- CRYSVITA$107
- Ozempic$102
- RYBELSUS$102
How this compares
$29,139 in reported general payments places this provider in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 363 | $540,166 |
| TrulicityDulaglutide | 197 | $274,173 |
| Tresiba Flextouch U-200Insulin Degludec | 182 | $245,224 |
| MounjaroTirzepatide | 126 | $211,788 |
| JardianceEmpagliflozin | 226 | $191,266 |
| FarxigaDapagliflozin Propanediol | 190 | $170,558 |
| ProliaDenosumab | 74 | $127,809 |
| RybelsusSemaglutide | 85 | $104,101 |
| Humalog Kwikpen U-200Insulin Lispro | 36 | $82,514 |
| Tresiba Flextouch U-100Insulin Degludec | 83 | $62,759 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 19 | $61,945 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 368 | $60,717 |
| Humalog Kwikpen U-100Insulin Lispro | 153 | $60,515 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $57,156 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 34 | $55,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $304 | $673,023525 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Humalog | $196 | $508,570368 claims |
| AmgenProlia, Evenity (2 Syringes) | $175 | $189,75393 claims |
| AstraZenecaFarxiga | $21,886 | $170,558190 claims |
| Sanofi-aventis U.S. LLCLantus | $103 | $8,77943 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $147 | $5,557445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Burlington
- Thomas OconnellBurlington$805K
- Mark WarrenGreenville$915K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- John BuseChapel Hill$460K
- Denis BeckerRaleigh$459K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.